[ad_1]
The British vaccine, on the other hand, is unlikely to get the green light in January.
The European Medicines Agency (EMA) will rule on the approval of the American biotechnology company Moderna’s vaccination against coronavirus as soon as possible, the agency said in a statement Monday.
The EMA Committee for Medicinal Products for Human Use (CHMP) will meet shortly to discuss the vaccination of Moderna,
reported the European Medicines Agency, which moved from London to Amsterdam after the UK split from the EU. The agency will hold its next meeting on Wednesday.
If approved, Moderna will be the second Covid-19 vaccine licensed in the European Union. On December 21, the EMA approved a vaccine developed by the US pharmaceutical company Pfizer and its German partner, BioNTech, which has been in use in EU member states since last week.
Moderna announced Monday that it will produce at least 600 million doses of the vaccine in 2021, 100 million more than previously planned. Currently, the company is working on investments and loans to expand its capacity to 1 billion doses, writes MTI. The drug company said it had already delivered 18 million doses of the vaccine to the US government under a 200 million dose contract. It has a contract with the Canadian government to supply 40 million servings.
The EMA indicated last week that although the British pharmaceutical company AstraSeneca and the University of Oxford were approved in the UK on Wednesday, it is unlikely to be licensed in the European Union in January. While the United States and Great Britain have urgently licensed the marketing of two vaccines, the EMA is under great pressure to speed up the authorization process, mainly from Germany.
[ad_2]
